Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout

BMC Musculoskeletal Disorders

Volumn 14, Issue , 2013, Pages

  Dalbeth, Nicola ^a   House, Meaghan E ^a   Horne, Anne ^a   Taylor, William J ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF OTAGO WELLINGTON   (New Zealand)

Author keywords

Creatinine; Gout; Kidney; Tophus

Indexed keywords

ALLOPURINOL; COLCHICINE; CORTICOSTEROID; CREATININE; DIURETIC AGENT;

ADULT; ARTHROPATHY; ARTICLE; CLINICAL ASSESSMENT; CORTICOSTEROID THERAPY; CREATININE CLEARANCE; DISEASE ASSOCIATION; ETHNICITY; FEMALE; GOUT; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PAIN ASSESSMENT; PATIENT GLOBAL ASSESSMENT SCORE; PROSPECTIVE STUDY; SCORING SYSTEM; SUBCUTANEOUS TOPHUS; VISUAL ANALOG SCALE;

ADULT; AGED; CREATININE; FEMALE; FOREIGN-BODY REACTION; GOUT; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; URIC ACID;

EID: 84890459340     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-14-363     Document Type: Article

References (24)

1. Cellular characterization of the gouty tophus: a quantitative analysis. Dalbeth N, Pool B, Gamble GD, Smith T, Callon KE, McQueen FM, Cornish J, Arthritis Rheum 2010 62 5 1549 1556 10.1002/art.27356 20131281
2. The diagnosis of gout and gout arthritis. Hench PS, J Lab Clin Med 1936 22 48 55
3. Tophaceous gout: a clinical and radiographic assessment. Nakayama DA, Barthelemy C, Carrera G, Lightfoot RW Jr, Wortmann RL, Arthritis Rheum 1984 27 4 468 471 10.1002/art.1780270417 6712761 (Pubitemid 14134790)
4. Rapid development of gouty tophi after diuretic therapy. Wordsworth BP, Mowat AG, J Rheumatol 1985 12 2 376 377 4032412 (Pubitemid 15025388)
5. Does prolonged systemic glucocorticoid use increase risk of tophus formation among gouty arthritis patients? Raso AA, Sto Nino OV, Li-Yu J, Int J Rheum Dis 2009 12 3 243 249 10.1111/j.1756-185X.2009.01418.x 20374354
6. Tophaceous gout in patients with renal transplants treated with cyclosporine A. Baethge BA, Work J, Landreneau MD, McDonald JC, J Rheumatol 1993 20 4 718 720 8496871 (Pubitemid 23138866)
7. Tophaceous joint disease strongly predicts hand function in patients with gout. Dalbeth N, Collis J, Gregory K, Clark B, Robinson E, McQueen FM, Rheumatology (Oxford) 2007 46 12 1804 1807 10.1093/rheumatology/kem246 17982165 (Pubitemid 350168295)
8. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. Khanna PP, Nuki G, Bardin T, Tausche AK, Forsythe A, Goren A, Vietri J, Khanna D, Health Qual Life Outcomes 2012 10 117 10.1186/1477-7525-10-117 22999027
9. Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography. Dalbeth N, Clark B, Gregory K, Gamble G, Sheehan T, Doyle A, McQueen FM, Ann Rheum Dis 2009 68 8 1290 1295 10.1136/ard.2008.094201 18708415
10. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Perez-Ruiz F, Martinez-Indart L, Carmona L, Herrero-Beites AM, Pijoan JI, Krishnan E, Ann Rheum Dis 2014 73 1 177 182 10.1136/annrheumdis-2012-202421 23313809
11. Preliminary criteria for the classification of the acute arthritis of primary gout. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF, Arthritis Rheum 1977 20 3 895 900 10.1002/art.1780200320 856219
12. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. Horne R, Weinman J, J Psychosom Res 1999 47 6 555 567 10.1016/S0022-3999(99)00057-4 10661603 (Pubitemid 30029305)
13. Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. Dalbeth N, Petrie KJ, House M, Chong J, Leung W, Chegudi R, Horne A, Gamble G, McQueen FM, Taylor WJ, Arthritis Care Res (Hoboken) 2011 63 11 1605 1612 10.1002/acr.20570 22034122
14. Development and validation of the health assessment questionnaire II: a revised version of the health assessment questionnaire. Wolfe F, Michaud K, Pincus T, Arthritis Rheum 2004 50 10 3296 3305 10.1002/art.20549 15476213 (Pubitemid 39372007)
15. Prediction of creatinine clearance from serum creatinine. Cockcroft DW, Gault MH, Nephron 1976 16 1 31 41 10.1159/000180580 1244564
16. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: modification of diet in renal disease study group. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, Ann Intern Med 1999 130 6 461 470 10.7326/0003-4819-130-6-199903160-00002 10075613 (Pubitemid 29135798)
17. Studies of uric acid pool size and turnover rate. Scott JT, Holloway VP, Glass HI, Arnot RN, Ann Rheum Dis 1969 28 4 366 373 10.1136/ard.28.4.366 5794063
18. Reduced secretion of proinflammatory cytokines of monosodium urate crystal-stimulated monocytes in chronic renal failure: an explanation for infrequent gout episodes in chronic renal failure patients? Schreiner O, Wandel E, Himmelsbach F, Galle PR, Marker-Hermann E, Nephrol Dial Transplant 2000 15 5 644 649 10.1093/ndt/15.5.644 10809805 (Pubitemid 30242982)
19. American college of rheumatology guidelines for management of gout: part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, et al. Arthritis Care Res (Hoboken) 2012 64 10 1431 1446 10.1002/acr.21772 23024028
20. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A, Arthritis Rheum 2002 47 4 356 360 10.1002/art.10511 12209479 (Pubitemid 34856121)
21. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Roddy E, Zhang W, Doherty M, Ann Rheum Dis 2007 66 10 1311 1315 10.1136/ard.2007.070755 17504843 (Pubitemid 47492473)
22. Primary care providers' knowledge, beliefs and treatment practices for gout: results of a physician questionnaire. Harrold LR, Mazor KM, Negron A, Ogarek J, Firneno C, Yood RA, Rheumatology (Oxford) 2013 52 9 1623 1629 10.1093/rheumatology/ket158 23620554
23. Dual energy computed tomography in tophaceous gout. Choi HK, Al-Arfaj AM, Eftekhari A, Munk PL, Shojania K, Reid G, Nicolaou S, Ann Rheum Dis 2009 68 10 1609 1612 10.1136/ard.2008.099713 19066180
24. Progress in measurement instruments for acute and chronic gout studies. Grainger R, Taylor WJ, Dalbeth N, Perez-Ruiz F, Singh JA, Waltrip RW, Schlesinger N, Evans R, Edwards NL, Sivera F, Diaz-Torne C, MacDonald PA, McQueen FM, Schumacher HR, J Rheumatol 2009 36 10 2346 2355 10.3899/jrheum. 090371 19820224